B. Reigner and K. Blesch, Estimating the starting dose for entry into humans: principles and practice, European Journal of Clinical Pharmacology, vol.57, issue.12
DOI : 10.1007/s00228-001-0405-6

Y. Zhou, Choice of designs and doses for early phase trials, Fundamental and Clinical Pharmacology, vol.14, issue.3, pp.373-381, 2004.
DOI : 10.1016/S0197-2456(01)00205-7

L. Aarons, M. Karlsson, and F. Mentré, Role of modelling and simulation in Phase I drug development, European Journal of Pharmaceutical Sciences, vol.13, issue.2, pp.115-137, 2001.
DOI : 10.1016/S0928-0987(01)00096-3

D. Food and . Administration, Guideline for the format and content of the human pharmacokinetics and bioavailability section of an application Available from URL: http://www.fda.gov, 1987.

J. Dingemanse and S. Appel-dingemanse, Integrated??Pharmacokinetics??and Pharmacodynamics in??Drug??Development, Clinical Pharmacokinetics, vol.57, issue.2, pp.713-750, 2007.
DOI : 10.2165/00003088-200746090-00001

R. Gieschke and J. Steimer, Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development, European Journal of Drug Metabolism and Pharmacokinetics, vol.13, issue.1, pp.49-58, 2000.
DOI : 10.1007/BF03190058

D. Food and . Administration, Innovation or stagnation: critical path opportunities report Available from URL, 2006.

J. Chien, S. Friedrich, and M. Heathman, Pharmacokinetics/pharmacodynamics and the stages of drug development: Role of modeling and simulation, The AAPS Journal, vol.7, issue.3, pp.544-59, 2005.
DOI : 10.1208/aapsj070355

G. Pillai, F. Mentré, and J. Steimer, Non-Linear Mixed Effects Modeling ??? From Methodology and Software Development to Driving Implementation in Drug Development Science, Journal of Pharmacokinetics and Pharmacodynamics, vol.72, issue.6, pp.161-83, 2005.
DOI : 10.1007/s10928-005-0062-y

S. Retout and F. Mentré, Optimization of Individual and Population Designs Using Splus, Journal of Pharmacokinetics and Pharmacodynamics, vol.30, issue.6, pp.417-460, 2003.
DOI : 10.1023/B:JOPA.0000013000.59346.9a

I. Boutron, F. Tubach, and B. Giraudeau, Methodological Differences in Clinical Trials Evaluating Nonpharmacological and Pharmacological Treatments of Hip and Knee Osteoarthritis, JAMA, vol.290, issue.8, pp.1062-70, 2003.
DOI : 10.1001/jama.290.8.1062

R. Development and C. Team, R: A language and environment for statistical computing Available from URL: http://www.R-project.org [13] Food and Drug Administration. Guidance for Industry: Population Phar- macokinetics Available from URL, 1999.

V. Bhattaram, B. Booth, and R. Ramchandani, Impact of pharmacometrics on drug approval and labeling decisions: A survey of 42 new drug applications, The AAPS Journal, vol.7, issue.3, pp.503-512, 2005.
DOI : 10.1208/aapsj070351

R. Bruno, N. Vivier, and C. Veyrat-follet, Population pharmacokinetics and pharmacokineticpharmacodynamic relationships for docetaxel, Investigational New Drugs, vol.19, issue.2, pp.163-172, 2001.
DOI : 10.1023/A:1010687017717

K. Margolin, T. Synold, and J. Longmate, Methodologic guidelines for the design of high-dose chemotherapy regimens, Biology of Blood and Marrow Transplantation, vol.7, issue.8, pp.414-446, 2001.
DOI : 10.1016/S1083-8791(01)80009-4

E. Strevel, N. Chau, and G. Pond, Improving the Quality of Abstract Reporting for Phase I Cancer Trials, Clinical Cancer Research, vol.14, issue.6, pp.1782-1789, 2008.
DOI : 10.1158/1078-0432.CCR-07-4886